Quiz|Articles|December 14, 2025

NeurologyLive® Brain Games: December 14, 2025

Author(s)Marco Meglio, Louie Pasculli

Listen

0:00 / 0:00

Key Takeaways

NeurologyLive Brain Games offers weekly quizzes on diverse neurology topics, engaging professionals in clinical and historical knowledge testing.
The quiz series covers a wide range of neurological conditions, including dementia, epilepsy, and movement disorders, with a focus on current themes like FcRn-blocking therapies.
Participants are encouraged to contribute by submitting quiz questions and sharing their results, fostering a collaborative and interactive learning environment.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

Welcome to NeurologyLive^® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.

Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.

This week's questions includes the theme of FcRn-blocking therapies in neurology.

Click here to check out the prior iterations of Brain Games.

Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email: [email protected].

Which best describes the primary mechanism by which FcRn-blocking agents reduce pathogenic IgG levels?

In generalized myasthenia gravis (gMG), FcRn blockers primarily improve symptoms through which immunologic effect?

Compared to IVIG, FcRn blockers most notably differ in which pharmacologic characteristic?

How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!

How many questions did you get correct?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

Latest CME

Video

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

NeurologyLive® Brain Games: December 14, 2025

Key Takeaways

Newsletter

Related Content

Beyond Dravet and LGS: Elizabeth Thiele, MD, PhD, on New Data for Epidiolex in DEEs

NDA Accepted for Narcolepsy Oxybate TRN-257, Gene Therapy ETX101 Early Promise in Dravet, Bexicaserin's Impact on Developmental Encephalopathies

Improving Outcomes for Older Adults With Epilepsy: Anny Reyes, MD

NeurologyLive® Friday 5 — December 12, 2025

Investigational TRPM8 Antagonist Elismetrep Achieves Positive Phase 2b Data in Acute Migraine

Latest CME

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis

NDA Accepted for Narcolepsy Oxybate TRN-257, Gene Therapy ETX101 Early Promise in Dravet, Bexicaserin's Impact on Developmental Encephalopathies

Survey identifies Fever-Related Seizure Reduction as Key Feature of CDKL5 Deficiency Disorder

Beyond Dravet and LGS: Elizabeth Thiele, MD, PhD, on New Data for Epidiolex in DEEs